The first comprehensive text on dyslipidemia from a major academic institution, this book covers all aspects of dyslipidemia as it relates to human disease, including coronary artery disease, cerebrovascular disease, peripheral vascular disease, and pancreatitis. The material is presented in a clinician-friendly format and includes references for additional reading. Reflecting current guidelines from the National Cholesterol Education Program, the book explains why, when, and how to treat dyslipidemia. Coverage includes dietary treatment, drug treatment, and recommendations for special populations such as patients with coronary heart disease, patients at high risk for coronary heart disease, patients with diabetes, women, older adults, young adults, and racial and ethnic groups.

Dyslipidemia has a complex pathophysiology consisting of various genetic, lifestyle, and environmental factors. It has many adverse health impacts, notably in the development of chronic non-communicable diseases. Significant ethnic differences exist due to the prevalence and types of lipid disorders. While elevated serum total- and LDL-cholesterol are the main concern in Western populations, in other countries hypertriglyceridemia and low HDL-cholesterol are more prevalent. The latter types of lipid disorders are considered as components of the metabolic syndrome. The escalating trend of obesity, as well as changes in lifestyle and environmental factors will make dyslipidemia a global medical and public health threat, not only for adults but for the pediatric age group as well. Several experimental and clinical studies are still being conducted regarding the underlying mechanisms and treatment of dyslipidemia. The current book is providing a general overview of dyslipidemia from diverse aspects of pathophysiology, ethnic differences, prevention, health hazards, and treatment.

Dyslipidemia is a major risk factor for cardiovascular disease, which is the leading cause of morbidity and mortality around the globe, particularly among aging populations. Lipoprotein disorders, frequently encountered by clinicians, require early recognition and treatment. In this book, we assembled a group of world-renowned scholars in their field to address major areas in lipoprotein disorders that are imminently relevant to clinicians and other healthcare providers. Areas discussed include an overview of lipid metabolism, a complex topic, presented in a simplified and rational way. We also highlight recent developments in the field including dyslipidemias characterized by nontraditional lipid biomarkers. Furthermore, we discuss the pathogenesis of atherosclerosis and the role of dyslipidemia. Other chapters include the assessment of primary and secondary causes of dyslipidemia. Targets for treatment as well as the role of major therapeutic agents including statins and PCSK9 inhibitors are also discussed in light of the most recent guidelines by major international organizations. This is in addition to an overview of lifestyle and dietary modification as well as alternative options for dyslipidemia management. Furthermore, dyslipidemia in special populations is emphasized including various ethnic groups as well as those with HIV disease, chronic kidney disease, among others. The role of adiposity including brown fat together with highlights on lipidomics and dyslipidemias characterized by nontraditional lipid biomarkers is also highlighted. We believe that this volume will serve as a valuable resource, not only for clinicians and other healthcare providers, but for students and research scholars as well.

Dyslipidemia affects almost half of American adults and is the most prevalent manageable risk factor for atherosclerosis. Lipid disorders often co-occur with other prevalent conditions such as diabetes and kidney disease; they are also often a concern with certain medication regimens (such as anti-retroviral and certain anti-psychotic agents). Proper treatment of dyslipidemia can reduce the risk of peripheral arterial disease, revascularization procedures, nonfatal myocardial infarction, stroke, and cardiac death. However, only 20% of adults meet the national guidelines for cholesterol control. As part of the Oxford American Cardiology Library, this practical handbook is designed to serve as a concise yet authoritative resource on diagnosing and treating dyslipidemia. The book is tailored to the needs of busy health care professionals treating patients in various clinical settings, and focuses on presenting essential information to clinicians who are at the forefront of the diagnosis and management of dyslipidemia. Featuring evidence-based, concise yet comprehensive discussion of key clinical concepts in addition to numerous figures, tables and illustrations, this pocket-sized handbook will serve as an invaluable guide to healthcare professionals.

The first comprehensive text on dyslipidemia from a major academic institution, this book covers all aspects of dyslipidemia as it relates to human disease, including coronary artery disease, cerebrovascular disease, peripheral vascular disease, and pancreatitis. The material is presented in a clinician-friendly format and includes references for additional reading. Reflecting current guidelines from the National Cholesterol Education Program, the book explains why, when, and how to treat dyslipidemia. Coverage includes dietary treatment, drug treatment, and recommendations for special populations such as patients with coronary heart disease, patients at high risk for coronary heart disease, patients with diabetes, women, older adults, young adults, and racial and ethnic groups.

Pediatric lipidology is a relatively new field of pediatrics. Premature cardiovascular diseases account for 30% of mortality in the United States. There is a heightened awareness regarding early recognition, prevention and management of childhood dyslipidemia. This book fulfils the need for a concise, quick-reference guide on clinical approach to the management of pediatric lipid disorders. Rational and optimal medical practice approaches are outlined throughout the text. Current clinical guidelines for treatment of genetic and acquired pediatric dyslipidemias are reviewed with an emphasis on new data and novel therapeutic options. This book is aimed to guide clinical decisions and improve care of at-risk youth in the primary prevention of premature atherosclerotic cardiovascular disease. Written by experts in the field, Pediatric Dyslipidemia includes the most up-to-date scientific and clinical information for pediatricians, endocrinologists, primary care practitioners and any other medical practitioners treating children with dyslipidemia.

This book presents state of the art knowledge on dyslipidemia in stroke, covering both basic and clinical aspects in detail. The focus is in particular on two major themes: the clinical significance of dyslipidemia in stroke and the treatment of dyslipidemia in stroke patients. Readers will find up-to-date information on lipid metabolism, biomarkers, and advances in treatment options, including novel biologic drugs. Specific management considerations and pitfalls are also discussed. The individual components of pathophysiology, treatment, and key issues are addressed with the aid of complementary illustrations that facilitate understanding of practical aspects and enable the reader to retrieve fundamental information quickly. This book is timely in bringing together within one volume the most important current knowledge on dyslipidemia in stroke. It will be invaluable for stroke physicians, pharmacists, and students seeking to acquire up-to-date knowledge.

Dyslipidemia is a major risk factor for cardiovascular events, cardiovascular mortality, and all-cause mortality. The earlier in life dyslipidemia is treated, the better the prognosis. The current book is an excellent one on dyslipidemia written by experts on this topic. This book includes 12 chapters including 5 on lipids, 4 on hypercholesterolemia in children, and 3 on the treatment of dyslipidemia. This book should be read by all health care professionals taking care of patients, including pediatricians since atherosclerotic cardiovascular disease begins in childhood.

Dyslipidemia, and particularly hypercholesterolemia, remains a main cardiovascular disease risk factor, partly reversible with the improvement of life-style, including dietary, habits. Even when a pharmacological treatment is begun, dietary support to lipid-lowering is always desired. This book will provide a selection of new evidence on the possible lipid-lowering effects of some dietary and medicinal plant components, reporting some interesting reviews, experimental data and results from clinical trials. The book is adapted for experts in nutrition but also for all scientists involved in cardiovascular disease prevention.

Dyslipidemia Essentials integrates the latest clinical guidelines and trials into a practical step-by-step guide to the management of dyslipidemia. Important clinical trials, common management pitfalls, and other cardiovascular risk reduction measures are also emphasized.